Sequential therapy with sunitinib and sorafenib in metastatic hepatocellular carcinoma

Investigational New Drugs

Volumn 30, Issue 4, 2012, Pages 1768-1772

  Ahn, Hee Kyung ^a   Lee, Soohyeon ^a   Sun, Jong Mu ^a   Lee, Jeeyun ^a   Park, Se Hoon ^a   Park, Joon Oh ^a   Park, Young Suk ^a   Kang, Won Ki ^a   Lim, Ho Yeong ^a  

^a Sungkyunkwan University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOTOXIC AGENT; SORAFENIB; SUNITINIB;

ADRENAL METASTASIS; ADULT; ADVANCED CANCER; AGED; ARTICLE; ASCITES; BLOOD TOXICITY; BONE METASTASIS; CANCER STAGING; CHEMOEMBOLIZATION; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HAND FOOT SYNDROME; HUMAN; HYPERBILIRUBINEMIA; INFECTION; LIVER CELL CARCINOMA; LUNG METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; RETROSPECTIVE STUDY; SIDE EFFECT; SKIN; THROMBOCYTOPENIA; TREATMENT FAILURE; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CARCINOMA, HEPATOCELLULAR; DISEASE PROGRESSION; FEMALE; HUMANS; INDOLES; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PROTEIN KINASE INHIBITORS; PYRIDINES; PYRROLES; TIME FACTORS; TREATMENT OUTCOME;

EID: 84866733361     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-011-9707-4     Document Type: Article

References (17)

1. El-Serag HB, Rudolph KL (2007) Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 132:2557-2576
2. Cheng AL, Kang YK, Chen Z et al (2009) Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10:25-34
3. Llovet JM, Ricci S, Mazzaferro V et al (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378-390
4. Wilhelm SM, Carter C, Tang L et al (2004) BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64:7099-7109
5. Faivre S, Demetri G, Sargent W, Raymond E (2007) Molecular basis for sunitinib efficacy and future clinical development. Nat Rev Drug Discov 6:734-745
6. Demetri GD, van Oosterom AT, Garrett CR et al (2006) Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 368:1329-1338
7. Dudek AZ, Zolnierek J, Dham A et al (2009) Sequential therapy with sorafenib and sunitinib in renal cell carcinoma. Cancer 115:61-67
8. Eichelberg C, Heuer R, Chun FK et al (2008) Sequential use of the tyrosine kinase inhibitors sorafenib and sunitinib in metastatic renal cell carcinoma: a retrospective outcome analysis. Eur Urol 54:1373-1378
9. Escudier B, Goupil MG, Massard C, Fizazi K (2009) Sequential therapy in renal cell carcinoma. Cancer 115:2321-2326
10. Hiles JJ, Kolesar JM (2008) Role of sunitinib and sorafenib in the treatment of metastatic renal cell carcinoma. Am J Health Syst Pharm 65:123-131
11. Merseburger AS, Simon A, Waalkes S, Kuczyk MA (2009) Sorafenib reveals efficacy in sequential treatment of metastatic renal cell cancer. Expert Rev Anticancer Ther 9:1429-1434
12. Richards TM, Plowman PN, Reznek R, Ball SA (2009) A crossover response to sequential use of sunitinib after sorafenib in a patient with metastatic renal cell carcinoma. Clin Oncol (R Coll Radiol) 21:633-634
13. Zimmermann K, Schmittel A, Steiner U et al (2009) Sunitinib treatment for patients with advanced clear-cell renal-cell carcinoma after progression on sorafenib. Oncology 76:350-354
14. Llovet JM, Bruix J (2008) Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol 48(Suppl 1): S20-S37
15. Zhu AX, Duda DG, Sahani DV, Jain RK (2009) Development of sunitinib in hepatocellular carcinoma: rationale, early clinical experience, and correlative studies. Cancer J 15:263-268
16. Faivre S, Raymond E, Boucher E et al (2009) Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study. Lancet Oncol 10:794-800
17. Huitzil-Melendez FD, Capanu M, O'Reilly EM et al (2010) Advanced hepatocellular carcinoma: which staging systems best predict prognosis? J Clin Oncol 28:2889-2895